CoChat

New trends in advanced parkinson disease stage therapy

Open access
Kolesárová, Mária, Franko, Ondrej, Kolesár, Dalibor, Gažová, Andrea, Kyselovič, Ján · 2023 · Česká a slovenská farmacie

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

The aim of the study was to point out the contribution of new invasive therapeutic procedures in the treatment of advanced stages of Parkinson's disease (PD) in comparison with classical oral pharmacotherapy. Data originated from a group of 43 patients with PD, 39% (17) with classic treatment, 23% (10) with intestinal gel of methyl ester levodopa (Duodopa), 19% (8) of patients were using subcutaneous delivery of apomorphine (APO) and the same quantity of patients had undergone deep brain stimulation (DBS). Majority of patients had advanced stages of PD, stage 4, by standards of Hoehn and Yahr scale (Hoehn and Yahr, 1967). Research observed improvement in majority of patients with novel treatments. A positive effect was also noted in the reduced need for oral therapy, where there was a significant decrease in all new therapies. Benefits were observed in the amount of antiparkinsonic drugs taken per os, where we observed reduction in all new therapies. A positive effect of the new therapeutic approaches in reducing "off" periods in patients has also been noted. In the case of Duodopa and DBS, the "off" period was shortened up to 50% and in the apomorphine pump up to 40%. Patients also reported reduction of some symptoms like rigidity, tremor and bradykinesis while dyskinesis still remains suba challenge. On the basis of the obtained results, it can be concluded that new therapeutic procedures for PCh will make it possible to manage symptoms typical of advanced stages of the disease, which without these procedures would lead to disability, which is the main reason for their indication. However, in early stages, well responding patients or in slow progressing disease oral antiparkinsonics are remaining as golden standard of treatment. This is not just due to good response but also because these classic drug formulations are significantly less expensive. In Slovakia, novel treatments are accessible through healthcare insurance only after secondary revision by insurance company doctors.

Overview

Integrity signals

Registry

Crossref · 10.5817/csf2023-1-37

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Research works printed but not linked: 6

  1. Švihovec, 2018, a kol. Farmakologie
  2. 2004, Růžička E., Urgošík D., Jech R., Serranová T., Volfová M., Roth J., Vymazal J., Mečíř P., Nováková L., Nováková O., Ulmanová O., Brožová H., Dušek P., Špačková N., Liščák R., Vladyka V. Hluboká mozková stimulace v léčbě Parkinsonovy nemoci a třesu: Pražská zkušenost 1998-2003. Čes, Slov. Neurol. N, 67, 423
  3. Valkovič, 2006, Súčasný pohľad na Parkinsonovu chorobu, Via pract, 3, 256
  4. Richter, 2011, Súčasný pohľad na liečbu Parkinsonovej choroby, Edukafarm MediNews, 1, 37
  5. 2020, Karadağ Y. S., Saltoğlu T., Küçükdağli F. E., Öztürk Ö., Köseoğlu H. T., Altiparmak E. Comprehensive assessment od levodopa-carbidopa intestinal gef for Turkish advanced Parkinson's disease patients, Turkish Journal of Medical Sciences, 51, 84
  6. Bohušová, 2020, Analýza vplyvu antiparkinsoník na poruchy kontroly impulzov zisťovaných pomocou metódy samohodnotenia pacientmi, Folia Pharmaceutica cassoviensia, II, 7

Cited by

See all 2

Metadata

Authors
Kolesárová, M., Franko, O., Kolesár, D., Gažová, A., & Kyselovič, J.
Venue
Česká a slovenská farmacie
Publisher
Solen s.r.o.
Published
2023-01-01
Volume
72
Issue
1
Pages
37-44
ISSN
  • 1210-7816 (ISSN-L)
  • 1805-4439
OpenAlex
W4322757328
Cited by
2
References
25
Citations by year
2025: 1 · 2024: 1
FWCI
0.34
Type
journal article
Language
cs
Open access
Locations
  • Česká a slovenská farmacie (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
advanced Parkinson's disease, deep brain stimulation, Duodopa, off periods, Hoehn and Yahr stage, dyskinesia, treatment costs, insurance coverage
MeSH terms
Administration, Oral, Apomorphine, Esters, Humans, Parkinson Disease, Slovakia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.